Comparative study of mezlocillin versus cefotaxime single-dose prophylaxis in patients undergoing vaginal hysterectomy

W. D. Hager, Richard L Sweet, D. Charles, B. Larsen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The literature confirms the benefit of antibiotic prophylaxis to reduce postoperative febrile and infectious morbidity in women undergoing vaginal hysterectomy; however, the ideal antibiotic to use prophylactically has not been determined. In this prospective, randomized, double-blind, multicenter study, the prophylactic efficacy of single-dose mezlocillin (4 gm) was compared with cefotaxime (1 gm). Each drug regimen was administered within five to 130 minutes prior to commencement of surgery. Thirty-eight of 41 (93%) patients receiving mezlocillin and 43 of 44 (98%) patients receiving cefotaxime had no evidence of infectious morbidity. There was no significant difference in outcome between the two groups. Because information on the pharmacodynamics of mezlocillin in pelvic tissues is scant, patients at one site were also evaluated for serum and uterine tissue mezlocillin levels. Serum samples obtained at the time the uterus was removed contained from 81.2 to 358 μg mezlocillin/ml with an average serum concentration of 207.5 μg/ml. The average tissue level was 117.2 μg/ml and ranged from 27% to 98% of the serum levels.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume45
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Mezlocillin
Vaginal Hysterectomy
Cefotaxime
Serum
Morbidity
Antibiotic Prophylaxis
Double-Blind Method
Multicenter Studies
Uterus
Fever
Anti-Bacterial Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparative study of mezlocillin versus cefotaxime single-dose prophylaxis in patients undergoing vaginal hysterectomy. / Hager, W. D.; Sweet, Richard L; Charles, D.; Larsen, B.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 45, No. 1, 1989, p. 63-69.

Research output: Contribution to journalArticle

@article{b869b911b8dd4cb9a7197c82b635f52a,
title = "Comparative study of mezlocillin versus cefotaxime single-dose prophylaxis in patients undergoing vaginal hysterectomy",
abstract = "The literature confirms the benefit of antibiotic prophylaxis to reduce postoperative febrile and infectious morbidity in women undergoing vaginal hysterectomy; however, the ideal antibiotic to use prophylactically has not been determined. In this prospective, randomized, double-blind, multicenter study, the prophylactic efficacy of single-dose mezlocillin (4 gm) was compared with cefotaxime (1 gm). Each drug regimen was administered within five to 130 minutes prior to commencement of surgery. Thirty-eight of 41 (93{\%}) patients receiving mezlocillin and 43 of 44 (98{\%}) patients receiving cefotaxime had no evidence of infectious morbidity. There was no significant difference in outcome between the two groups. Because information on the pharmacodynamics of mezlocillin in pelvic tissues is scant, patients at one site were also evaluated for serum and uterine tissue mezlocillin levels. Serum samples obtained at the time the uterus was removed contained from 81.2 to 358 μg mezlocillin/ml with an average serum concentration of 207.5 μg/ml. The average tissue level was 117.2 μg/ml and ranged from 27{\%} to 98{\%} of the serum levels.",
author = "Hager, {W. D.} and Sweet, {Richard L} and D. Charles and B. Larsen",
year = "1989",
language = "English (US)",
volume = "45",
pages = "63--69",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Comparative study of mezlocillin versus cefotaxime single-dose prophylaxis in patients undergoing vaginal hysterectomy

AU - Hager, W. D.

AU - Sweet, Richard L

AU - Charles, D.

AU - Larsen, B.

PY - 1989

Y1 - 1989

N2 - The literature confirms the benefit of antibiotic prophylaxis to reduce postoperative febrile and infectious morbidity in women undergoing vaginal hysterectomy; however, the ideal antibiotic to use prophylactically has not been determined. In this prospective, randomized, double-blind, multicenter study, the prophylactic efficacy of single-dose mezlocillin (4 gm) was compared with cefotaxime (1 gm). Each drug regimen was administered within five to 130 minutes prior to commencement of surgery. Thirty-eight of 41 (93%) patients receiving mezlocillin and 43 of 44 (98%) patients receiving cefotaxime had no evidence of infectious morbidity. There was no significant difference in outcome between the two groups. Because information on the pharmacodynamics of mezlocillin in pelvic tissues is scant, patients at one site were also evaluated for serum and uterine tissue mezlocillin levels. Serum samples obtained at the time the uterus was removed contained from 81.2 to 358 μg mezlocillin/ml with an average serum concentration of 207.5 μg/ml. The average tissue level was 117.2 μg/ml and ranged from 27% to 98% of the serum levels.

AB - The literature confirms the benefit of antibiotic prophylaxis to reduce postoperative febrile and infectious morbidity in women undergoing vaginal hysterectomy; however, the ideal antibiotic to use prophylactically has not been determined. In this prospective, randomized, double-blind, multicenter study, the prophylactic efficacy of single-dose mezlocillin (4 gm) was compared with cefotaxime (1 gm). Each drug regimen was administered within five to 130 minutes prior to commencement of surgery. Thirty-eight of 41 (93%) patients receiving mezlocillin and 43 of 44 (98%) patients receiving cefotaxime had no evidence of infectious morbidity. There was no significant difference in outcome between the two groups. Because information on the pharmacodynamics of mezlocillin in pelvic tissues is scant, patients at one site were also evaluated for serum and uterine tissue mezlocillin levels. Serum samples obtained at the time the uterus was removed contained from 81.2 to 358 μg mezlocillin/ml with an average serum concentration of 207.5 μg/ml. The average tissue level was 117.2 μg/ml and ranged from 27% to 98% of the serum levels.

UR - http://www.scopus.com/inward/record.url?scp=0024529806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024529806&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024529806

VL - 45

SP - 63

EP - 69

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 1

ER -